Analyst Price Target is $1.50
▲ +127.27% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for DarioHealth in the last 3 months. The average price target is $1.50, with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 127.27% upside from the last price of $0.66.
Current Consensus is
Moderate Buy
The current consensus among 2 polled investment analysts is to moderate buy stock in DarioHealth. This rating has held steady since January 2025, when it changed from a Buy consensus rating.
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Read More
